Equities research analysts at StockNews.com began coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Free Report) in a note issued to investors on Friday. The firm set a “sell” rating on the biopharmaceutical company’s stock.
Akari Therapeutics Stock Performance
AKTX opened at $3.84 on Friday. The firm has a 50-day moving average of $3.51 and a 200 day moving average of $2.45. Akari Therapeutics has a fifty-two week low of $1.08 and a fifty-two week high of $4.40.
About Akari Therapeutics
Want More Great Investing Ideas?
Featured Stories
- Five stocks we like better than Akari Therapeutics
- What is a Stock Market Index and How Do You Use Them?
- Does A&F’s Q2 Earnings Win Point to a Strong Holiday Season?
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Best Buy Stock Flashes Bullish Signal, Challenges Remain
- What is a Bond Market Holiday? How to Invest and Trade
- Affirm Shows Buy-Now-Pay-Later Is Here to Stay in Latest Results
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.